|
 |
Huntingtons Disease > Antibody
The following information is about Antibody.
Antibody Defined
A protein that is produced when the immune system detects a substance that is believed to be foreign. Antibodies inhibit the activity of these substances.
This definition is in context to Huntingtons Disease. See more contextual defintions for Antibody.
Type 1 Diabetes
Published August 29, 2008, 12:58 pm, New York Times
In-Depth From A.D.A.M. Treatment Insulin is essential for strict control of blood glucose levels in type 1 diabetes. Tight blood glucose control is the best way to prevent major complications in type 1 diabetes, including those that affect the kidneys, eyes, nerve pathways, and blood vessels.
Diabetes, Type 1
Published August 29, 2008, 12:57 pm, New York Times
Government agencies, universities and corporations frequently enroll patients in studies designed to test the effectiveness of new drugs, procedures and medical devices.
ERBITUX(R) Phase 3 BMS-099 Lung Cancer Study Secondary Endpoint Update: Overall Survival Results Announced
Published August 29, 2008, 9:40 am, Centre Daily Times
ImClone Systems Incorporated (NASDAQ: IMCL) today announced overall survival results from BMS CA225-099 (BMS-099), an open-label Phase 3 study of ERBITUX(R) (cetuximab) in combination with a taxane and carboplatin in the first-line treatment of all histological subtypes of advanced non-small cell lung cancer (NSCLC).
Randomized Phase 2 Study Of IMC-A12 And IMC-1121B For Advanced Prostate Cancer Commences Patient Enrollment
Published August 29, 2008, 7:10 am, Medical News Today
ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that its disease-directed Phase 2 clinical trial in patients with advanced prostate cancer randomized to treatment with either IMC-A12 or IMC-1121B plus mitoxantrone and prednisone has commenced patient enrollment.
Morphotek(R), Inc. Expands Its Phase II Trial Site Selections In The European Union - Pancreatic Cancer Treatment
Published August 29, 2008, 7:09 am, Medical News Today
Morphotek®, Inc., a subsidiary of Eisai Corporation of North America, announced that it has opened clinical sites in the European Union (EU) as part of the company's MORAb-009 Phase II study. The study is evaluating MORAb-009, a monoclonal antibody to mesothelin, as a first-line treatment for patients with pancreatic cancer.
Early Trigger For Type-1 Diabetes Found In Mice, Stanford Scientists Report
Published August 29, 2008, 6:11 am, Medical News Today
Scientists at the Stanford University School of Medicine are shedding light on how type-1 diabetes begins. Doctors have known the disease is caused by an autoimmune attack on the pancreas, but the exact trigger of the attack has been unclear.
HGSI completes enrolment in second phase-3 Lymphostat-B trial
Published August 29, 2008, 4:52 am, PharmaBiz
Human Genome Sciences, Inc (HGSI) has completed enrolment and initial dosing in BLISS-76, the second of two pivotal phase-3 randomized clinical trials of LymphoStat-B (belimumab) in patients with active systemic lupus erythematosus (SLE). Belimumab is being developed by HGS and GlaxoSmithKline (GSK) under a co-development and commercialization agreement entered into in August 2006.
Patient Recruitment In Psoriasis Trial For Arana's Inflammatory Drug ART621 Completed; Results Expected In Q1 2009
Published August 29, 2008, 3:09 am, Medical News Today
Biotechnology company Arana Therapeutics Limited (ASX: AAH) announced that it has completed recruitment in its Phase II dose-ranging psoriasis study for its anti-inflammatory drug ART621. Completion of recruitment means that formal results of the study should be available in early 2009.
Immunomedics Announces Fiscal 2008 Results
Published August 28, 2008, 1:00 pm, GlobeNewswire via Yahoo! Finance
MORRIS PLAINS, N.J., Aug. 28, 2008 -- Immunomedics, Inc. , a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported revenues of $1.0 million and a net loss of $6.9 million, or $0.09 per share, for the fourth quarter of fiscal year 2008, which ended June 30, 2008.
Medical Breakthrough Helping S.A. Cancer Patients
Published August 28, 2008, 11:04 am, WOAI San Antonio
Patients from as far as Laredo and Eagle Pass are coming to San Antonio to receive the new drug.
Are you looking for additional Huntingtons Disease > Antibody news? Try our new "Antibody News Focus" area.
Off-site Antibody Links, User Submitted
The following links have been collected through user bookmark submission in the Antibody category. Please note, because these resources are off-site we cannot guarantee the accuracy or quality of any information.
Thu Aug 28
Tue Aug 26
Mon Aug 25
- Melbourne doctors move closer to wonder cures
- Antibody Engineering Cuts Collateral Damage of Cancer Drugs: Killing cancer cells, while leaving normal tissue unscathed, is almost impossible. Nanotechnology may do the trick, but big pharmaceutical companies are far from embracing that strategy. In the meantime, highly-enginee red biological molecules will fill the void.
Fri Aug 22
- CSF B--lymphocyte chemoattractan t (CXCL13) in the ...[J Neurol. 2008] - PubMed Result: Norway, 2008 (abstract only). A chemical in the spinal fluid, B-lymphocyte attracting chemokine (CXCL13) may be diagnostic for neurological Lyme disease, as shown in this study of 59 consecutive patients referred for possible neuroborrelios is.
Thu Aug 21
Mon Aug 18
- Remembrance of viruses past : Nature News
- www.bioinf.org .uk : Dr. Andrew C.R. Martin's Group at UCL: This page provides an automatically updated summary of all antibody structures in the Protein Databank
- TheStar.com | News & Features | Antibodies from 1918 flu still work well, study says
If you would like to find additional social bookmark based links on the topic of we recommend the Open Tag Directory > Antibody. If you would like to find related tags we recommend Tag Patterns > Antibody
Off-site Antibody Research Links
If you still need additional information on Antibody then we suggest the following off-site resources. Please note, because these resources are off-site we cannot guarantee the accuracy or quality of any information.
Huntingtons Disease Topics
Everything you need to know about Huntingtons Disease
Huntingtons Disease
If you know the Huntingtons Disease Term Name use the links below to quickly jump to your desired focus.
Bookmark Us
The On Topic Network
This website is part of The On Topic Network.
Thank You
Huntingtons-Disease.On-Topic.net was developed by Odin Metatech, Inc and runs on the Odin Assemble platform.
Best Viewed With
License
This work is licensed under Creative Commons.